Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.
暂无分享,去创建一个
Mariano J. Alvarez | O. Podhajcer | M. Alvarez | F. Pitossi | C. Carbone | A. Bravo | H. E. Chuluyan | V. Lutzky | F. Prada | Podhajcer | E. Salvatierra | H. Chuluyan | H. | I. | Alicia | Eduardo Chuluyan | Bravo | L. Osvaldo
[1] E. Sage,et al. Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells , 2005, Journal of cellular physiology.
[2] E. Sage,et al. SPARC and tumor growth: Where the seed meets the soil? , 2004, Journal of cellular biochemistry.
[3] M. Colombo,et al. Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.
[4] William P Schiemann,et al. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. , 2003, Molecular biology of the cell.
[5] D. Bigner,et al. Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model* , 2003, The Journal of Biological Chemistry.
[6] M. Lagarde,et al. Platelets may inhibit leucotriene biosynthesis by human neutrophils at the integrin level , 2003, British journal of haematology.
[7] R. Brekken,et al. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.
[8] C. Berking,et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL‐8 , 2003, International journal of cancer.
[9] N. Lemke,et al. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. , 2002, Cancer research.
[11] C. Funk,et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.
[12] D. Livant,et al. Monocyte-Fibronectin Interactions, Via α5β1 Integrin, Induce Expression of CXC Chemokine-Dependent Angiogenic Activity1 , 2001, The Journal of Immunology.
[13] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[14] E. Sage,et al. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. , 2001, The Journal of clinical investigation.
[15] J. Trapani,et al. A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.
[16] F. Shanahan,et al. Immune privilege or inflammation? Insights into the Fas ligand enigma , 2001, Nature Medicine.
[17] P. Musiani,et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. , 2001, Blood.
[18] D. Hanahan,et al. MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.
[19] R. Savani,et al. Bleomycin-induced pulmonary injury in mice deficient in SPARC. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[20] W. Couser,et al. SPARC Regulates the Expression of Collagen Type I and Transforming Growth Factor-β1 in Mesangial Cells* , 1999, The Journal of Biological Chemistry.
[21] M. Ringuette,et al. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. , 1999, Gynecologic oncology.
[22] M. Webber,et al. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. , 1999, Cancer research.
[23] E. Sage,et al. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. , 1999, American journal of physiology. Lung cellular and molecular physiology.
[24] T. Mikkelsen,et al. Increased SPARC expression promotes U87 glioblastoma invasion in vitro , 1999, International Journal of Developmental Neuroscience.
[25] C. Van Waes,et al. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. , 1999, Cancer research.
[26] F. Dallegri,et al. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. , 1999, Journal of immunology.
[27] S. Rempel,et al. SPARC: a potential diagnostic marker of invasive meningiomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] G. Nabel,et al. Regulation of the proinflammatory effects of Fas ligand (CD95L). , 1998, Science.
[29] S. Nagata,et al. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand , 1998, Nature Medicine.
[30] M. Burdick,et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression , 1997, Journal of leukocyte biology.
[31] K. Ikai,et al. Human melanoma cells generate leukotrienes B4 and C4 from leukotriene A4 , 1997, Archives of Dermatological Research.
[32] O. Podhajcer,et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.
[33] O. Podhajcer,et al. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. , 1997, The Journal of investigative dermatology.
[34] R. Garofalo,et al. Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: nuclear translocation of the RelA transcription factor as a mechanism producing airway mucosal inflammation , 1996, Journal of virology.
[35] J. Tschopp,et al. Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.
[36] R. Berkowitz,et al. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.
[37] A. Anichini,et al. Interaction with fibronectin regulates cytokine gene expression in human melanoma cells , 1996, International journal of cancer.
[38] P. Chambon,et al. Comparative expression of the SPARC and stromelysin-3 genes in mammary tumours , 1996 .
[39] J. Gershenwald,et al. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. , 1995, Cancer research.
[40] H. Schreiber,et al. Inhibition of tumor growth by elimination of granulocytes , 1995, The Journal of experimental medicine.
[41] H. Mitani,et al. Human melanoma cells generate leukotriene B and C from leukotriene A , 1994 .
[42] A. Issekutz,et al. VLA-4 integrin can mediate CD11/CD18-independent transendothelial migration of human monocytes. , 1993, The Journal of clinical investigation.
[43] M. Iruela-Arispe,et al. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. , 1992, The Journal of biological chemistry.
[44] P. Prasit,et al. Translocation of HL-60 cell 5-lipoxygenase. Inhibition of A23187- or N-formyl-methionyl-leucyl-phenylalanine-induced translocation by indole and quinoline leukotriene synthesis inhibitors. , 1991, The Journal of biological chemistry.
[45] M. Walport,et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. , 1989, The Journal of clinical investigation.
[46] J. Schröder,et al. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. , 1987, Journal of immunology.
[47] M. Paulsson,et al. Calcium binding domains and calcium-induced conformational transition of SPARC/BM-40/osteonectin, an extracellular glycoprotein expressed in mineralized and nonmineralized tissues. , 1987, Biochemistry.
[48] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .
[49] L. Coussens,et al. Inflammatory Cells and Cancer: Think Different! , 2001 .
[50] Robert D. Goldman,et al. Cells: a laboratory manual , 1997 .
[51] L. Enquist,et al. Protocols for gene transfer in neuroscience : towards gene therapy of neurological disorders , 1996 .
[52] R. T. Oliver,et al. The immunological aspects of malignant disease. , 1975, The Practitioner.
[53] L. J. Reed. A simple method of estimating fifty per cent end-points. , 1938 .